As of Jul 29
| +1.53 / +1.35%|
The 22 analysts offering 12-month price forecasts for Edwards Lifesciences Corp have a median target of 119.50, with a high estimate of 135.00 and a low estimate of 83.00. The median estimate represents a +4.35% increase from the last price of 114.52.
The current consensus among 26 polled investment analysts is to Buy stock in Edwards Lifesciences Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.